Financial Data and Key Metrics Changes - Total revenue surged 568% year over year to $23.6 million in Q3 2025, driven by IMA's 76% quarter-to-quarter growth [9] - Adjusted EBITDA loss improved from $6.5 million in Q1 to $2.1 million in Q3, indicating operational leverage and a clear path to profitability [12][17] - Cash increased to approximately $82 million and Bitcoin holdings valued at around $40 million, resulting in total liquidity of about $120 million with zero debt [7][18] Business Line Data and Key Metrics Changes - IMA achieved $100 million annual recurring revenue (ARR) in the last 11 months, with projections to reach $300 million ARR by the end of 2026 [6] - Subscription rate for IMA stands at 80%, with an average order value increasing by 36% quarter over quarter to $150 [10][11] - Gross margin improved to 60% from 52%, reflecting enhanced profitability [10] Market Data and Key Metrics Changes - International markets now account for 56.5% of total revenue, with the U.S. being the top market followed by Canada, the U.K., Australia, and Singapore [10] - IMA has achieved over 420,000 customer purchases across 31 countries, indicating strong global demand [9] Company Strategy and Development Direction - The company aims to create a new category at the intersection of health and wealth, targeting $1 billion in annual revenue by 2030 [6] - A strategic divestment of non-core assets is underway to focus resources on IMA, the highest margin growth engine [14] - The company is leveraging partnerships with high-profile individuals to enhance brand visibility and credibility [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $180-$200 million in revenue for 2026, driven by international expansion and new product launches [18] - The company is strategically choosing to scale aggressively rather than prioritize short-term profitability, aiming to capture maximum market share [18] Other Important Information - The company has initiated a Bitcoin accumulation strategy, purchasing one Bitcoin daily since August 1, which is part of a sustainable framework to build shareholder value [8] - The recent $44 million funding round attracted notable investors, enhancing the company's financial position [6] Q&A Session Summary Question: Impressive payback period of 3.9 months - Management explained that the payback period has improved from four to five months at launch to 3.9 months now, indicating marketing efficiencies and strong unit economics [19][20] Question: Strong growth in international markets - Management noted that the U.S. market share has decreased from 70% to 46.5%, with significant growth observed in Canada, Europe, the Middle East, and Southeast Asia [21] Question: Need for additional capital for expansion - Management stated that with current liquidity, there is no expectation of needing new capital for expansion, emphasizing operational flexibility from recent fundraising [22][24]

Revenue Performance - Total revenue for Q3 2025 reached $23.6 million, a 568% increase year-over-year [13] - IM8's monthly revenue hit a record $9 million in October 2025, representing a 36% month-over-month growth from September [3] - IM8 is projected to achieve $180 to $200 million in revenue for FY 2026, translating to approximately $25 million in monthly revenue or $300 million ARR by year-end 2026 [20] - Prenetics expects Q4 2025 revenue for IM8 to be $28 million, representing a 63% quarter-over-quarter increase compared to Q3 2025 [19] - Revenue for the nine months ended September 30, 2025, was $55,832,000, a significant increase from $9,374,000 in the same period of 2024, representing a growth of 496% [34] - Revenue for the three months ended September 30, 2025, was $23,555,000, a 33.5% increase from $17,680,000 in the previous quarter and a significant increase from $3,528,000 in the same quarter last year [35] - Revenue from the IM8 business unit reached $17,214,000 for the three months ended September 30, 2025, compared to $9,754,000 in the previous quarter [37] - CircleDNA revenue for the three months ended September 30, 2025, was $2,353,000, up from $2,210,000 in the previous quarter [37] Financial Metrics - The company reported a gross margin of 60% in Q3 2025, with a payback period of 3.9 months, indicating strong unit economics [6] - Adjusted EBITDA loss improved to $(2.1) million in Q3 2025, a 49.6% decrease compared to Q3 2024 [13] - Gross profit for the same period was $14,024,000, compared to $7,289,000 in the previous quarter, reflecting an increase of 92.5% [35] - Loss from operations decreased to $6,164,000 for the three months ended September 30, 2025, down from $10,065,000 in the previous quarter [35] - Adjusted EBITDA for the three months ended September 30, 2025, was $(2,083,000), an improvement from $(4,132,000) in the previous quarter [36] - Loss from operations for the nine months ended September 30, 2025, was $24,591,000, slightly higher than the loss of $23,990,000 in 2024 [34] - Total comprehensive expense for the period was $(7,408,000), a decrease from $(12,406,000) in the previous quarter [35] - The company reported a loss for the period under IFRS of $(8,693,000) for the three months ended September 30, 2025, compared to $(12,727,000) in the previous quarter [36] Assets and Liabilities - Total assets as of September 30, 2025, were $196,507,000, a decrease from $199,106,000 as of June 30, 2025 [33] - Total liabilities decreased to $35,305,000 as of September 30, 2025, from $48,214,000 as of June 30, 2025 [33] - Current assets under IFRS as of September 30, 2025, were $38,276,000, significantly lower than $75,747,000 as of December 31, 2024 [38] Strategic Initiatives - Prenetics maintains approximately $120 million in total liquidity, including $82 million in cash and cash escrow, and zero debt [14] - The company has accumulated 387 BTC valued at approximately $41 million as part of its Bitcoin treasury strategy [15] - Prenetics is conducting a strategic review of non-core assets to focus on its highest-growth business unit, IM8 [17] - Management is focusing on new business strategies in genomics and precision oncology, particularly in early cancer detection [1] - The company completed the divestment of ACT Genomics on October 1, 2025, which is now excluded from continuing operations [28] Shareholder Information - Loss attributable to equity shareholders for the nine months ended September 30, 2025, was $30,208,000, compared to $29,962,000 in 2024 [34] - Basic loss per share for the nine months ended September 30, 2025, was $(2.26), compared to $(2.42) in 2024 [34] Cryptocurrency Holdings - Cryptocurrency assets increased to $28,334,000 as of September 30, 2025, up from $20,285,000 as of June 30, 2025 [33]

Core Insights - Prenetics Global Limited reported a significant increase in total revenue, surging 568% year-over-year to $23.6 million in Q3 2025, with a gross profit of $14.0 million, reflecting a 631.2% increase compared to Q3 2024 [14][25][9] - The company's IM8 brand achieved record monthly revenue of $9 million in October 2025, marking a 36% month-over-month growth from September [4][2] - IM8 is projected to reach $180 to $200 million in revenue for FY 2026, translating to approximately $25 million in monthly revenue or $300 million in annual recurring revenue (ARR) by the end of 2026 [21][11] Financial Performance - Q3 2025 financial highlights include a quarterly revenue of $23.6 million, a gross margin of 60%, and an adjusted EBITDA loss of $(2.1) million, improving from $(4.5) million in Q1 2025 [14][9][10] - The company reported a total of 420,000 customer purchases across 31 countries, with international markets contributing 56.5% of IM8's revenue [5][4] - The average order value for new customers increased to $150 in October 2025, up 36% from the previous month [6][8] Strategic Developments - Prenetics completed a $44 million equity offering in October 2025, attracting strategic investors, which positions the company for accelerated global expansion [3][10] - The company maintains a strong balance sheet with approximately $120 million in total liquidity and zero debt, allowing for aggressive scaling without dilutive capital needs [10][15] - Prenetics is executing a strategic review of non-core assets to focus on its highest-growth unit, IM8, following the successful divestiture of ACT Genomics [18][19] Market Positioning - IM8 is recognized for having the fastest growth trajectory in the global supplements industry, achieving $108 million in ARR within 11 months of launch [25][2] - The company is also pioneering a dual-engine strategy by integrating Bitcoin as a strategic treasury asset, currently holding 387 BTC valued at approximately $41 million [16][26] - Prenetics aims to replicate the success of direct-to-consumer brands like Hims & Hers, leveraging strong unit economics and a subscription-based revenue model [11][21]

Core Insights - Prenetics Global Limited will release its financial results for Q3 2025 on November 10, 2025, before market open, and will hold its first earnings conference call at 8:30 a.m. Eastern Time on the same day [1][2] Company Overview - Prenetics is a leading health sciences company focused on health and longevity, with its flagship consumer brand IM8 co-founded with David Beckham, which has achieved $100 million in annual recurring revenue within 11 months of launch, marking the fastest growth in the supplements industry [3] - The company has established a Bitcoin Treasury, purchasing 1 Bitcoin per day, totaling 382 BTC as of November 4, 2025, positioning itself at the intersection of health innovation and digital assets [4]

Core Insights - Prenetics Global Limited's IM8 brand achieved approximately $108 million in annualized recurring revenue (ARR) just 11 months post-launch, marking a significant milestone in its growth trajectory [1][4][9] - The company reported a record monthly revenue of $9 million in October, reflecting a 32% increase from September's $6.8 million, driven by strong subscriber growth and improved retention metrics [4][5] - Prenetics recently completed a $44 million equity offering, which is expected to facilitate accelerated global expansion and enhanced marketing initiatives [3][4] Financial Performance - IM8's monthly revenue reached $9 million in October, representing a 32% month-over-month growth from September [5] - The brand has delivered 13 million servings to over 420,000 customers across 31 countries since its launch [5] - IM8 projects a minimum of $10 million in monthly revenue by December 2025, with total revenues expected to be approximately $60 million for FY 2025 and between $180 million and $200 million for FY 2026 [12] Strategic Initiatives - The recent equity raise positions IM8 for aggressive scaling, including exploring partnerships with elite athletes and global wellness thought leaders [4][5] - The launch of the Daily Ultimate Longevity product has contributed to an increase in average order value from approximately $110 to $145, indicating strong consumer demand [5] - Prenetics aims to continue scaling IM8 through 2026 with initiatives focused on global distribution, product innovations, and retention efforts [8] Market Position - IM8 is recognized as the fastest-growing supplement brand globally, achieving $100 million in ARR within just 11 months of launch, surpassing previous records in the supplements industry [9] - The company is also pioneering in the intersection of health innovation and digital assets, having established a Bitcoin Treasury by purchasing 1 Bitcoin per day, totaling 380 BTC as of November 4, 2025 [10]

Core Insights - Prenetics Global Limited has acquired 100 Bitcoin at an average price of $109,594 per Bitcoin, increasing its total Bitcoin holdings to 378 BTC valued at approximately $46 million [1][10] - The acquisition is part of a strategic capital deployment following a successful $44 million equity offering, which was oversubscribed and attracted high-quality strategic investors [2][3] - The company maintains a strong balance sheet with $127 million in total liquidity, consisting of $86 million in cash and $41 million in Bitcoin holdings, while having zero debt [4] Financial Performance - Prenetics' IM8 supplement brand has achieved $100 million in annual recurring revenue within just 11 months of launch, marking the fastest growth in the global supplements industry [5][9] - The company has provided FY2026 revenue guidance for IM8, expecting revenues between $180 million and $200 million [6] Strategic Vision - The CEO's manifesto outlines a vision for a "health-and-wealth" platform, combining growth in the wellness market with strategic Bitcoin accumulation, aiming to create unprecedented shareholder value [7] - Prenetics is recognized as the first consumer health company to establish a Bitcoin Treasury, reinforcing its position at the intersection of health innovation and digital assets [10]

Core Insights - Prenetics Global Limited has published a comprehensive manifesto detailing its strategic vision, combining healthcare growth with Bitcoin treasury management [2][3] - The company's flagship brand, IM8, achieved $100 million in annual recurring revenue within 11 months of launch, marking the fastest growth in the supplement industry [3][6] - Prenetics projects revenue of $180 to $200 million for FY 2026 [3][6] Healthcare Engine (IM8) - IM8 is co-founded by David Beckham and supported by tennis champion Aryna Sabalenka, contributing to its rapid growth [3][6] - The brand's success generates substantial cash flows that facilitate sophisticated Bitcoin treasury management [5] Bitcoin Treasury Engine - As of October 29, 2025, Prenetics holds 277 BTC and employs a disciplined strategy of acquiring 1 BTC daily [4][7] - This Bitcoin treasury is described as a "fortress of value," providing financial resilience and appreciation potential [4] Synergy Between Healthcare and Bitcoin - The integration of IM8's growth with Bitcoin treasury management creates a virtuous cycle, enhancing both healthcare expansion and financial appreciation [5]

Core Viewpoint - Prenetics Global Limited has successfully closed a public offering, raising approximately $44 million to support its global expansion and Bitcoin accumulation strategy [3]. Group 1: Offering Details - The offering included 2,722,642 Class A ordinary shares and associated warrants, with a combined offering price of $16.08 per share [1]. - Class A Common Warrants have an exercise price of $24.12 per share, while Class B Common Warrants are priced at $32.16 per share, representing premiums of 50% and 100% respectively [2]. - The gross proceeds from the offering were approximately $44 million, down from a previously announced $48 million [3]. Group 2: Use of Proceeds - The proceeds will be utilized for the global expansion of IM8, Prenetics' flagship consumer brand, and for the strategic accumulation of Bitcoin as part of its health and wealth strategy [3][7]. - Prenetics has established a Bitcoin Treasury, purchasing 1 Bitcoin per day, totaling 275 BTC as of October 27, 2025 [8]. Group 3: Company Background - Prenetics is a leading health sciences company co-founded with David Beckham, known for its rapid growth in the supplement industry, achieving $100 million in annual recurring revenue within 11 months of launch [7]. - The company is recognized for pioneering at the intersection of health innovation and digital assets [8].

Core Viewpoint - Prenetics Global Limited has successfully closed a public offering, raising approximately $44 million to support its global expansion and Bitcoin accumulation strategy [3]. Group 1: Offering Details - The offering included 2,722,642 Class A ordinary shares and associated warrants at a combined price of $16.08 per share [1]. - Class A Common Warrants have an exercise price of $24.12 per share, while Class B Common Warrants are priced at $32.16 per share, representing a 50% and 100% premium to the offering price respectively [2]. - The gross proceeds from the offering were approximately $44 million, which is lower than the previously announced $48 million [3]. Group 2: Use of Proceeds - The proceeds from the offering will be utilized for the global expansion of IM8, Prenetics' flagship consumer brand, and for the strategic accumulation of Bitcoin as part of its health and wealth strategy [3][7]. - Prenetics has established a Bitcoin Treasury, purchasing 1 Bitcoin per day, totaling 275 BTC as of October 27, 2025 [8]. Group 3: Company Background - Prenetics is recognized as a leading health sciences company, co-founded with David Beckham, and has achieved $100 million in annual recurring revenue within 11 months of launching its IM8 brand, marking the fastest growth in the supplements industry [7].

JUST IN: Nasdaq-listed healthcare company Prenetics raises $48 MILLION to buy more BitcoinPrenetics has bought 1 Bitcoin per day since August 1Their long-term goal is to buy $1 BILLION Bitcoin by 2026 🔥 https://t.co/MtdrH8t8f6 ...